Search results
9 sty 2023 · The adenoviral S-based vaccine candidate failed to control the SARS-CoV-2 brain replication, reducing the brain viral load only when it was combined with a nucleocapsid-based vaccine...
25 cze 2024 · Neurological post-acute sequelae of COVID-19 (neuroPASC) may be prevented by vaccination against SARS-CoV-2, even when other symptoms develop (breakthrough infection). Mechanisms underlying...
20 cze 2024 · Klein and colleagues show that low-dose COVID-19 vaccination prevents breakthrough infection-mediated hippocampal dysfunction and cognitive memory decline in mouse models.
1 lut 2024 · Here, we show that midbrain dopamine (DA) neurons derived from human pluripotent stem cells (hPSCs) are selectively susceptible and permissive to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
1 lut 2024 · Yang et al. now show that human stem-cell-derived dopaminergic neurons are susceptible to SARS-CoV-2, triggering inflammation and senescence. The study further identifies three FDA-approved drugs capable of reversing these cellular phenotypes.
The data indicated an association between Ad26.COV2.S and an increased risk of GBS (observed-to-expected [OE] ratio at 21 days, 3.79; 95% CI, 2.88-4.88; OE ratio at 42 days, 2.34; 95% CI, 1.83-2.94), which was not observed for the mRNA vaccines (OE ratio less than 1 for both mRNA vaccines).11.
Two shots of the mRNA vaccines were needed to induce peak antibody and memory B cell responses against SARS-CoV-2 in naïve patients, whereas only one shot induced peak responses in convalescent patients.
